Global B2B Pharmaceutical Sourcing · Dossier Licensing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Rilonacept bulk supplier for pharma manufacturers

Rilonacept 220mg/vial Suppliers & Bulk Manufacturers

Available Forms: injection

Available Strengths: 220mg/vial

Originator reference: Arcalyst (USA/EU) (brand names belong to their owners and are shown only to identify the originator medicine)

Category: Immune Disorder

Rilonacept (Arcalyst) is a subcutaneous IL-1 inhibitor used to treat Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS). It works by blocking interleukin-1, a protein that drives inflammation in these rare auto-inflammatory disorders. Rilonacept is available as an 80 mg/mL solution in pre-filled syringes.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Rilonacept? List it or send an offer →

Product Description:

Rilonacept is an interleukin-1 trap: a fusion protein combining the extracellular domains of the IL-1 receptor and its accessory protein with the Fc portion of human IgG1. It acts as a decoy receptor, binding IL-1 beta — and also IL-1 alpha and the IL-1 receptor antagonist — with high affinity before they can reach cell-surface receptors. Its broader binding distinguishes it from antibodies specific to IL-1 beta alone.

It is used for cryopyrin-associated periodic syndromes, for deficiency of the IL-1 receptor antagonist, and for recurrent pericarditis, where it both treats the acute episode and reduces recurrence — an indication that expanded its market well beyond the rare autoinflammatory syndromes it was developed for. It is given by weekly subcutaneous injection after a loading dose. Because it blocks a central innate immune signal, serious infection risk rises, tuberculosis must be excluded before starting, and live vaccines are avoided. Injection site reactions are very common and lipid changes are reported.

Sourcing notes. Originator biologic, on patent, no biosimilar. Cold chain. Supplied as lyophilised powder for reconstitution. Weekly dosing makes annual cost high per patient; the pericarditis indication drives most current demand.

How Rilonacept is supplied today, and licensing ahead of patent expiry

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access
Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing
A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives
Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule
Ask about Rilonacept supply →
Back to Listing

Frequently Asked Questions

Arcalyst (Rilonacept) is developed and sold by Kiniksa Pharmaceuticals (developed by Regeneron). PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.

Related Products

Vamorolone

Strength:
40 mg/mL

Form: Oral suspension

Originator reference: Agamree (USA/EU)

View Details
Imiglucerase

Strength:
200 U/vial, 400 U/vial

Form: Injection

Originator reference: Cerezyme (USA/EU/ India)

View Details
Cevimeline HCl

Strength:
30mg

Form: Capsules

Originator reference: Evoxac (USA)

View Details
Caplacizumab

Strength:
10mg

Form: Injection

Originator reference: Cablivi (USA/EU)

View Details
Etrasimod Arginine

Strength:
2 mg, 4 mg, 6 mg

Form: Tablets

Originator reference: Velsipity (USA)

View Details
Guselkumab Injection

Strength:
100 mg/mL, 200 mg/2 mL (SC); 200 mg/20 mL (IV)

Form: Pre-filled syringe, pen (subcutaneous); vial (IV infusion)

Originator reference: Tremfya (Johnson & Johnson)

View Details
Risankizumab Injection

Strength:
150 mg/mL (SC); 180 mg, 360 mg on-body injector; 600 mg/10 mL (IV)

Form: Pre-filled pen, syringe, on-body injector (SC); vial (IV)

Originator reference: Skyrizi (AbbVie)

View Details
Ixekizumab Injection

Strength:
80 mg/mL

Form: Pre-filled autoinjector, pre-filled syringe (subcutaneous)

Originator reference: Taltz (Eli Lilly)

View Details
Enquire Now

Usually answered within 48 hours | GMP documents shared before you commit

Subscribe to Our Newsletter

Stay updated on pharma trends and sourcing opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.
WhatsApp us